Statement: the secondary trial reported more cases of Haematemesis, but the primary trial had more total cases of DIASTOLIC DYSFUNCTION across both its cohorts.
Primary_evidence: Adverse Events 1:   Total: 58/305 (19.02%)   FEBRILE NEUTROPENIA * 12/305 (3.93%)   NEUTROPENIA * 4/305 (1.31%)   ANAEMIA * 2/305 (0.66%)   LEUKOPENIA * 1/305 (0.33%)   PANCYTOPENIA * 1/305 (0.33%)   THROMBOCYTOPENIA * 1/305 (0.33%)   DISSEMINATED INTRAVASCULAR COAGULATION * 0/305 (0.00%)   ATRIAL FIBRILLATION * 1/305 (0.33%)   DIASTOLIC DYSFUNCTION * 1/305 (0.33%)   PERICARDIAL EFFUSION * 1/305 (0.33%) Adverse Events 2:   Total: 50/304 (16.45%)   FEBRILE NEUTROPENIA * 12/304 (3.95%)   NEUTROPENIA * 1/304 (0.33%)   ANAEMIA * 0/304 (0.00%)   LEUKOPENIA * 0/304 (0.00%)   PANCYTOPENIA * 0/304 (0.00%)   THROMBOCYTOPENIA * 0/304 (0.00%)   DISSEMINATED INTRAVASCULAR COAGULATION * 1/304 (0.33%)   ATRIAL FIBRILLATION * 1/304 (0.33%)   DIASTOLIC DYSFUNCTION * 0/304 (0.00%)   PERICARDIAL EFFUSION * 0/304 (0.00%)
Secondary_evidence: Adverse Events 1:   Total: 31/52 (59.62%)   Febrile neutropenia 2/52 (3.85%)   Left ventricular dysfunction 2/52 (3.85%)   Sinus tachycardia 1/52 (1.92%)   Congenital arterial malformation 1/52 (1.92%)   Diarrhoea 5/52 (9.62%)   Salivary hypersecretion 1/52 (1.92%)   Enteritis 1/52 (1.92%)   Abdominal pain 1/52 (1.92%)   Vomiting 1/52 (1.92%)   Stomatitis 1/52 (1.92%)   Haematemesis 1/52 (1.92%)